a public good project by the
Synthesis
Company
of California

© 2026

Marion Flipo | doi.page

0 works0 citations0 h-index

Marion Flipo

Inserm(FR)Université de Lille(FR)Institut Pasteur de Lille(FR)Living Systems (United States)(US)

Publications by Year

Research Areas

Tuberculosis Research and Epidemiology, Cancer therapeutics and mechanisms, Biochemical and Molecular Research, Antibiotic Resistance in Bacteria, Chemical Synthesis and Analysis

Most-Cited Works

→ Tuberculosis: The drug development pipeline at a glance(2012)172 cited
→ Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420(2017)141 cited
→ Hydroxamates: Relationships between Structure and Plasma Stability(2009)104 cited
→ Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria(2023)97 cited
→ Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles(2017)96 cited
→ Ethionamide Boosters: Synthesis, Biological Activity, and Structure−Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors(2011)84 cited

→ Novel Selective Inhibitors of the Zinc Plasmodial Aminopeptidase PfA-M1 as Potential Antimalarial Agents(2007)

72 cited

→ Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors(2011)70 cited

→ Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis(2019)67 cited

→ Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches(2014)64 cited